Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2007

View Archived Issues

Minodronate effective in Japanese women with postmenopausal osteoporosis

Symphony GenIsis acquired by Isis

Patient enrollment completed in Barrier's pivotal phase III trial of Hyphanox

Osteopontin: a novel target for the treatment of uveoretinitis

Local delivery of VIP-loaded liposomes effectively protects ocular tissue in rats with EAU

Preclinical efficacy, pharmacokinetics and safety of the ETB agonist SPI-1620

Actelion begins phase IIa proof-of-concept study of Zavesca for CF

First patients enrolled in Transgene's phase I trial of HCV vaccine TG-4040

Recordati to acquire Orphan Europe

Positive results for Diffusion's phase I safety trial of TSC

BioLineRx in-licenses novel peptide for cancer

Phase II studies commence for PYY3-36 nasal spray to treat obesity

RDEA-119 enters human clinical trials in advanced cancer patients

Merck & Co. donates cervical cancer vaccine Gardasil in lowest income nations

Nemonoxacin's preclinical profile reported

AR-2474: a novel topical antibiotic against MRSA infections

Novel contraceptive agents imparted by Pharmacopeia

Recent Ferring patent reports novel agents for use in critical care medicine

Taxotere receives FDA approval for expanded SCCHN indication

Novel immunosuppressant agents disclosed in recent Synta patent

Oncolytics Biotech reports positive interim data from combination Reolysin/radiation trial

Sublinox shows promise in comparative study for sleep disturbances

Novel antihypertensive agents prepared and tested at Torrent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...